Lumos Pharma(LUMO) - 2019 Q1 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Delaware 42-1491350 Washington, D.C. 20549 FORM 10-Q ý Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2019. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 NEWLINK GENETICS CORPORATION (Exact name of Registrant as specified in Its Charter) (State or ...